Skip to main content
. Author manuscript; available in PMC: 2022 Mar 30.
Published in final edited form as: Blood Cells Mol Dis. 2017 Aug 8;67:148–154. doi: 10.1016/j.bcmd.2017.08.006

Table 1.

Similar alloimmunization rates in patients with SCA receiving chronic red cell transfusions with general versus minority donor inventories.

Study Donor inventory Number of
patients		 Number of red cell unit
exposures in study		 Overall antibody rate
(events/100 units
transfused)		 Rh antibody rate (events/
100 units transfused)		 Overall allo-immunization
prevalence (%)
STOP trial General 63 1830 0.49 0.21 14%
SIT trial General 99 3235 0.28 0.16 6%
Philadelphia single center Minority donor program 123 44,210 0.30 0.21 58%

STOP, Stroke Prevention Trial in Sickle Cell Anemia: a Multi-Center Transfusion Trial [20]; SIT, Silent Cerebral Infarct Multi-Center Clinical Trial [8]; Philadelphia single center [26].